Atriva Therapeutics takes part in four conferences in the upcoming months

Atriva Therapeutics takes part in four conferences in the upcoming months

 Tübingen (Germany), September 4, 2019 – Atriva Therapeutics GmbH, a biopharma­ceutical company pioneering the development of host-targeting antiviral therapies, today announced its participation in four upcoming partnering conferences worldwide.

Dr. Rainer Lichtenberger, CEO of Atriva, will represent the Company and will be available for networking and one-on-one meetings at the following events:

12^th Annual International Partnering Conference BioPharm America
September 11^th – 12^th, 2019, Boston Convention & Exhibition Center, Boston, MA, USA
Dr. Rainer Lichtenberger, CEO of Atriva, will give a Company Presentation on September 12th, 3:00 – 3:10 pm EST.
ebdgroup.knect365.com/biopharm-america

19^th Annual Biotech in Europe Forum (Sachs Conference)
September 25^th – 26^th, 2019, Congress Center Basel, Switzerland
Dr. Rainer Lichtenberger, CEO of Atriva, will give a Company Presentation on September 25^th, 12:20 CET. Dr. Lichtenberger will also participate in the “Vaccines & Infectious Disease Panel” on September 25^th, 17:05 CET.
www.sachsforum.com/bef19-about.html

25^th Annual International Partnering Conference BIO-Europe^®
November 11^th – 13^th, 2019, Hamburg Messe, Hamburg, Germany
Dr. Rainer Lichtenberger, CEO of Atriva, will give a Company Presentation.
ebdgroup.knect365.com/bioeurope

6^th China Healthcare Summit 2019
November 18^th – 20^th, 2019, Jing An Shangri-La, Shanghai, China
www.biocentury.com/conferences/china-healthcare-summit-2019

About Atriva Therapeutics GmbH

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies setup by a team of leading scientists in viral research and seasoned industry experts. The company aims to develop new antiviral therapies against different respiratory viral infections. The lead product ATR-002 is a first-in-class host-targeting agent, inhibiting viral replication in influenza and other respiratory infections, an area of high unmet medical need. ATR-002 is under clinical development in a Phase I trial to evaluate safety and tolerability in healthy subjects. The Company owns seven broad patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2039. Atriva Therapeutics is located in Tübingen and Frankfurt, Germany.

For further information, please visit www.atriva-therapeutics.com or see our LinkedIn profile  Atriva Therapeutics GmbH.